tbuckley/cabot-search huggingface dataset:
Cordycepin inhibits polyadenylation and induces cell death in multiple myeloma cells
Authors: Lisa S. Chen, Varsha Gandhi
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

630 

Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) are indolent cancers, and hence are not amenable to traditional DNA-targeting strategies. Since MM and leukemia cells actively synthesize RNA for cellular physiological processes and for cell survival, we hypothesized that RNA processing events are potential therapeutic targets for these diseases. Processing of pre-mRNA into mature mRNA involves three major steps: 5’-end methylguanosine capping, 3’-end cleavage and polyadenylation, and intron splicing. The addition of a 3′-end poly(A) tail to eukaryotic mRNAs is required for the transport of RNA from the nucleus to the cytoplasm, translation efficiency, and the regulation of mRNA degradation. RNA poly(A) tail length has been shown to regulate RNA stability, and thus polyadenylation inhibition may be an attractive RNA-targeted strategy for the treatment of MM and CLL. Furthermore, several studies have illustrated that compared to normal cells, tumor cells have higher expression of poly(A) polymerase (PAP), the enzyme responsible for catalyzing poly(A)-tail addition. Based on these observations we hypothesized that PAP inhibition may be a potential target for cancer treatments. Our previous studies demonstrated that PAP inhibition could be achieved using C8-substituted adenosine analogs. Specifically, 8-amino-ATP, 8-azido-ATP and 8-chloro-ATP were shown to inhibit poly(A)-tail synthesis by yeast PAP causing chain termination ( J Biol Chem 279: 40405, 2004). To build upon these observations, a known polyadenylation inhibitor, cordycepin (3′-deoxyadenosine) was assessed in a MM cell line, MM.1S, in the presence of adenosine deaminase inhibitors coformycin and deoxycoformycin. Cordycepin inhibited MM.1S cell growth, and following continuous incubation for 48 and 72 hours, the IC50 for cordycepin was measured to be 10 μM and 2 μM, respectively. To determine if this inhibition was due to apoptosis induction, the treated cells were stained with Annexin V and analyzed using flow cytometry. Treatment with 10 μM of cordycepin resulted in 10% and 50% Annexin positive cells after 24 and 48 hours, respectively. Cells treated with 10 μM cordycepin had a time-dependent accumulation of the triphosphate metabolite, 3′dATP. At 6 hours, the intracellular level of 3′dATP was approximately 40 μM. This concentration has been shown to inhibit polyadenylation and is above the K m value (6 μM) measured for 3′dATP with yeast PAP. Taken together, the results presented here support the hypothesis that polyadenylation inhibition may prove to be a valuable strategy to target indolent cancers. Futher studies will be conducted to evaluate the downstream effects following PAP inhibition in this cell line.
SUBCLINICAL MYOCARDIAL ALTERATIONS IN CARDIAC SARCOIDOSIS
Authors: Cristina Di Stefano, Giulia Bruno, Gayatri Acharya, Rachel Le, Lynn Fussner, Patompong Ungprasert, Leslie Cooper, Lori Blauwet, Patricia Pellikka, Jay Ryu, Eva M. Carmona, Hector Villarraga
Journal: Journal of the American College of Cardiology (2017)
CARDIOVASCULAR MAGNETIC RESONANCE IN SURVIVORS OF SUDDEN CARDIAC ARREST: 14 YEAR EXPERIENCE FROM A TERTIARY REFERRAL CENTRE IN THE UNITED KINGDOM
Authors: Amrit Lota, John Baksi, Adam Tsao, Florence Mouy, Rebecca Wassall, Brian Halliday, Upasana Tayal, Cemil Izgi, Francisco Alpendurada, Evangelia Nyktari, Ricardo Wage, Peter Gatehouse, Philip Kilner, Raad Mohiaddin, David Firmin, James Ware, John Cleland, Stuart Cook, Dudley Pennell, Sanjay Prasad
Journal: Journal of the American College of Cardiology (2017)
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN THE EMERGENCY ROOM: RAPID EXCLUSION OF CORONARY ARTERY DISEASE AND THE FAST DIAGNOSIS OF ACUTE MYOCARDITIS USING LATE ENHANCEMENT BY COMPUTED TOMOGRAPHY
Authors: Pedro Gabriel Melo De Barros E. Silva, Luciana Baptista, Carlos Prazeres, Thiago Macedo, Marcio Sampaio, Jose Garcia, Valter Furlan
Journal: Journal of the American College of Cardiology (2017)
PROGNOSTIC STRATIFICATION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFACTION OVER TRANSTHORACIC ECHOCARDIOGRAPHY BY CMR
Authors: Gianluca Pontone, Daniele Andreini, Giovanni Ferro, Andrea Igoren Guaricci, Marco Guglielmo, Saima Mushtaq, Andrea Baggiano, Patrizia Carità, Mauro Pepi, Gianluca Pontone
Journal: Journal of the American College of Cardiology (2017)
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
Authors: Aimee Ginsburg Arlen, Thomas H. Cartwright, Lalan S. Wilfong, J. Russell Hoverman, Greg C Nelson, Brian Turnwald, Roy A. Beveridge
Journal: Journal of Clinical Oncology (2012)

e16536 Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 43,920 patients will be diagnosed in 2012 and 37,390 will die (Siegel, CA Cancer J Clin, 2012). Gemcitabine has long been the standard of care chemotherapy. Recent advances in treatment options have led to the utilization of a combination regimen (oxaliplatin, irinotecan, leucovorin, fluorouracil [FOLFIRINOX]) in patients with good Karnofsky performance status (PS). This regimen was compared to single-agent gemcitabine, presented at ASCO 2010 and recently published (Conroy, NEJM, 2011). This retrospective analysis was conducted to evaluate characteristics and overall survival (OS) of patients receiving FOLFIRINOX and gemcitabine-based treatments in a large outpatient community setting. Methods: Patients with advanced PC treated within The US Oncology Network and entered into the iKnowMed (iKM) database between June 2010 and November 2011 were included. Patterns of treatment were characterized by the median age at diagnosis, sex, PS, and first-line metastatic chemotherapy prescribed. The primary endpoints of the analysis were OS and uptake of FOLFIRINOX within the network. Results: Of the 717 patients identified within the iKM database, 13% received FOLFIRINOX and 87% gemcitabine-based therapy. Increased utilization of FOLFIRINOX for patients with good PS began in June 2010. For all patients (54% male), the median age at diagnosis was 67 years and the majority of patients (89%) had a PS of 70% or greater. The OS was significantly longer for FOLFIRINOX (8.4 months) versus gemcitabine (6.4 months) (p=0.036). OS was also significantly longer for PS of 70% or greater given FOLFIRINOX (9.0 months) versus gemcitabine (6.7 months) (p=0.022). After controlling for PS, the use of gemcitabine led to a shorter OS (HR 1.4; 95% CI: 1.02-2.01). Conclusions: Utilization of FOLFIRINOX has rapidly been adopted in patients with good PS after the publication of phase III trials. Our data in a community setting supports a survival advantage for FOLFIRINOX. Although the magnitude of benefit may be smaller in the community setting, we agree that should FOLFIRINOX become a standard of care for good PS patients.
MIDREGIONAL PROADRENOMEDULLIN: A PROGNOSTIC MARKER OF MORTALITY AND HEART FAILURE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Alexander Christian Falkentoft, Rasmus Rørth, Dan Eik Høfsten, Kasper Iversen, Thomas Engstrøm, Henning Kelbæk, Lene Holmvang, Martin Frydland, Klaus Kofoed, Jens Peter Goetze, Christian Torp-Pedersen, Lars Køber
Journal: Journal of the American College of Cardiology (2017)
Health Care for Older People
Authors: J. Grimley Evans
Journal: JAMA (1996)

The United States and Canada are 2 federal nations separated geographically by an arbitrary line of latitude but culturally by 200 years of history. The ancestry of their institutions lies respectively, albeit remotely, in the anarchy of frontiers and the order of empire. Different assumptions about the natural way to organize society emerge in the pattern of their health services. The United States presents to the world a vision of rampant entrepreneurialism bridled by the enlightened self-interest of citizens and spurred by sporadic pricks of compassion. Canada's more collectivist tradition emerges in a concern that its health services should make sense in the context of equity and the public health, an ideal that has yet to be fully realized.<sup>1</sup>It has, however, retained the tradition of the physician as a fee-paid professional, and only in the salaried medical staff of some primary health care centers in Quebec does one
Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).
Authors: Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, Adil Daud, Alfons JM van den Eertwegh, Lee D. Cranmer, Steven O'Day, Igor Puzanov, Jacob Schachter, Christian U. Blank, April K. Salama, Carmen Loquai, Janice M. Mehnert, Yang Wang, Scot Ebbinghaus, Soonmo Peter Kang, Wei Zhou, Antoni Ribas
Journal: Journal of Clinical Oncology (2015)

9040 Background: Pembrolizumab is approved for treating advanced MEL that progressed following IPI and, if BRAFV600 mutant, a BRAF inhibitor. In KEYNOTE-002 (NCT01704287), pembrolizumab significantly prolonged PFS compared with chemotherapy in IPI-R advanced MEL (P < .0001) and was associated with a lower rate of grade 3-5 AEs. Herein, we present the PRO analysis. Methods: Pts with advanced MEL that progressed within 6 mo after ≥2 IPI doses and, if BRAFV600 mutant, following a BRAF/MEK inhibitor, were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 wk or investigator’s choice of chemotherapy. Primary end points were PFS and OS. PROs were an exploratory end point with prespecified analysis. The EORTC QLQ-C30 was collected at baseline, wk 3, 6, 12, 24, 36, treatment discontinuation, and safety follow-up. The key PRO end points are the score change from baseline and the proportions of improvement/deterioration at wk 12 of the global health status score. A constrained longitudinal data analysis model assessed between-arm differences in all pts with ≥1 PRO assessment. Results: 520 of 540 enrolled pts were included in the PRO analysis. Baseline global health status scores were similar across treatment arms. Pembrolizumab-treated pts had significantly lesser decreases from baseline in the global health status scale score compared with control (Table). At wk 12, the proportion of pts with a ≥10-point decrease in global health status was 38% for control, 32% for pembrolizumab 2 mg/kg, and 27% for pembrolizumab 10 mg/kg. Pembrolizumab-treated pts had consistently lesser score changes from baseline for the different function and symptoms scales. Conclusions: In KEYNOTE-002, quality of life was maintained to a greater degree with pembrolizumab versus chemotherapy in IPI-R MEL. Clinical trial information: NCT01704287. Global Health Status Scale Score Baseline Wk 12 Change From Baseline, Least Squares Mean (95% CI) Mean SD Mean SD Control (n = 167) 64.0 21.9 59.0 23.2 –9.1 (–12.9, –5.4) Pembro 2 mg/kg (n = 176) 66.2 22.1 66.3 23.0 –2.6 (–6.2, 1.0)* Pembro 10 mg/kg (n = 177) 63.0 23.6 64.3 22.9 –2.6 (–6.0, 0.9)* *P = .01 versus control.
Estimation of NOD2/CARD15 Haplotypes and Their Impact on the Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Leukemia
Authors: Neema P Mayor, Bronwen E. Shaw, Hazael Maldonado-Torres, Louise Cooke, J. Alejandro Madrigal, Steven GE Marsh
Journal: Blood (2010)
Cardiac tolerability of trastuzumab in metastatic breast cancer (MBC) patients previously treated with high-dose chemotherapy (HDC) with autologous hemopoietic support: Retrospective analysis from Gruppo Italiano Trapianto Midollo Osseo (GITMO) Solid Tumor Working Party
Authors: C. Bengala, C. Zamagni, P. Pedrazzoli, P. Matteucci, A. Ballestrero, G. Da Prada, M. Martino, G. Rosti, M. Danova, G. Jovic, P. Conte
Journal: Journal of Clinical Oncology (2006)

10558 Background: HER-2 overexpression is associated to a poor prognosis in high-risk and MBC patients treated with HDC. HER-2 status is also a predictive factor of response to trastuzumab: when trastuzumab is administered in combination with or sequentially to chemotherapy, a significant DFS and/or survival improvement has been observed in HER2+ early and MBC. Unfortunately, in both settings, trastuzumab was associated with an increased risk of cardiac dysfunctions (CD). Patients and Methods: In order to evaluate the cardiac safety of trastuzumab after HDC, we have reviewed the clinical charts of HER2-overexpressing MBC patients treated with HDC and trastuzumab at 11 centres of the GITMO group. Age, baseline LVEF, radiation therapy on cardiac area, exposure to anthracycline, single or multiple transplant, high-dose agents, trastuzumab treatment duration were recorded as potential risk factors. Cardiac dysfunction (CD) was defined as: 1) decline of LVEF ≥ 10% to below 50%, 2) decline of LVEF between 5 and 9% to below 50% with symptomatic (NYHA class III-IV) congestive heart failure (CHF), 3) any symptomatic CHF event. Results: Fifty-three patients treated between 1999 and 2005 have been included in the analysis. Median age was 47 years (range 29–66). Median interval between HDC and trastuzumab was 6 months. Median LVEF at baseline was 60.5%; at the end of trastuzumab (data available for 28 patients only) it was 55% (p = 0.01). Five out of the 28 (17.9%) pts experienced CD. Two out of 53 (3.8%) pts developed a symptomatic (NYHA class III) CHF. Age ≥ 50 years was the only factor significantly associated with CD. However age ≥ 50 years and multiple transplant procedure were associated with a significant decline of LVEF (p: 0.02). Conclusion: The incidence of CD is not superior to that reported with trastuzumab after standard chemotherapy. However pts with age ≥ 50 years or receiving multiple course of HDC, should be considered at risk for CD. No significant financial relationships to disclose.
HORMONE REPLACEMENT THERAPY IS ASSOCIATED WITH LESS CORONARY ATHEROSCLEROSIS AND LOWER MORTALITY
Authors: Yoav Arnson, Alan Rozanski, Heidi Gransar, Yuka Otaki, Mhairi Doris, Frances Wang, John Friedman, Sean Hayes, Louise Thomson, Balaji Tamarappoo, Piotr Slomka, Damini Dey, Daniel Berman
Journal: Journal of the American College of Cardiology (2017)
Relationship among socioeconomic factors, distress, and quality of life (QOL) in cancer outpatients
Authors: K. Kobayashi, M. Shimonagayoshi, M. Kobayashi, M. Uno, K. Yamaguchi, S. Morita
Journal: Journal of Clinical Oncology (2004)

8127 Background:In 2002, a national survey to assess the socioeconomic status and distress of cancer patients using a semi-structured questionnaire was performed in Japan. To investigate relationships between patients' socioeconomic status and distress and their quality of life (QOL), the EORTC QLQ-C30 and the FACT-Sp were also given to patients in one institute, Saitama Cancer Center, and were analyzed two dimensionally. Methods:The impact of each item in the semi-structured questionnaire on the subscales of the QLQ-C30 and FACT-Sp was analyzed using one-way analysis of variance (ANOVA) and multivariate regression analysis with adjustment for gender, age, and cancer type. Results:A total of 210 cancer patients who used our outpatient clinic for chemotherapy were asked to enroll in this study. Of these, 130 answered all three questionnaires (male: 42%; average age: 59 y; PSR 0/1/2-: 25/64/11%; Breast/Lung/Gastrointestinal cancer/Other: 38/22/21/19%). ANOVA indicated a significant relationship between QOL and age, cancer type, PSR, occupation, and marital status. Multivariate analysis confirmed that a better PSR significantly correlated with a better QOL status in all subscales, and that having an occupation correlated with a better QOL in Physical Functioning (PF: p=0.014), but that a change in occupation (dismissal, layoff, or retirement) negatively correlated with PF (p=0.002), Role Functioning (RF: p=0.032), Emotional Functioning (EF: p=0.006), Cognitive Functioning (p<0.001), Social Functioning (p=0.004) and Financial Impact (p=0.021) of the QLQ-C30 and Spiritual Well-Being of the FACT Sp (SpWB:p=0.044). Unexpectedly, multivariate analysis indicated that having a partner negatively correlated with EF (p=0.005) and SpWB (0.038). Conclusions: Losing employment because of cancer had a very negative impact on patients' QOL. From examination of the narrative answers regarding patients' distress in the semi-structured questionnaire, it can be considered that both insufficient understanding of the patient's status by his/her partner and anxiety over the family's future might deteriorate patients' QOL in EF and SpWB. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ministry of Health, Labour and Welfare (Japan)
Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)
Authors: Agnieszka Pluta, Kamil Brzozowski, Konrad Stepka, Ewa Wawrzyniak, Anna Krawczynska, Anna Szmigielska-Kaplon, Olga Grzybowska-Izydorczyk, Magdalena Czemerska, Tomasz Gromek, Marek Hus, Grzegorz Helbig, Ewa Bodzenta, Sebastian Grosicki, Malgorzata Razny, Lukasz Bolkun, Janusz Kloczko, Wanda Knopinska-Posluszny, Agnieszka Piekarska, Andrzej Hellmann, Marta Sobas, Tomasz Wrobel, Elzbieta Patkowska, Ewa Lech-Maranda, Krzysztof Warzocha, Jerzy Holowiecki, Sebastian Giebel, Tadeusz Robak, Agnieszka Wierzbowska
Journal: Blood (2016)
CHEWING VERSUS TRADITIONAL SWALLOWING OF TICAGRELOR TO ACCELERATE PLATELET INHIBITION IN ST ELEVATION MYOCARDIAL INFARCTION: THE CHEERS-STEMI STUDY
Authors: Elad Asher, Shir Tal, Israel Mazin, Moshe Katz, Avi Sabbag, Ehud Regev, Victor Guetta, Amit Segev, Dan Elian, Israel Barbash, Paul Fefer, Roy Beigel, Shlomi Matetzky
Journal: Journal of the American College of Cardiology (2017)
MARKED RESPIRATORY RELATED VARIATION IN LVOT GRADIENTS IN HYPERTROPHIC CARDIOMYOPATHY IN OBESE HCM PATIENTS WITH SLEEP-DISORDERED BREATHING
Authors: Renuka Jain, Martin Osranek, M. Fuad Jan, Lindsey Kalvin, Susan Olet, Suhail Allaqaband, Bijoy Khandheria, A. Jamil Tajik
Journal: Journal of the American College of Cardiology (2017)
Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis
Authors: G. Di Lorenzo, S. De Placido, G. Cartenì, R. Autorino, A. Gonnella, M. Rizzo, S. Perdona, E. Ricevuto, M. Aieta, M. Ewer
Journal: Journal of Clinical Oncology (2009)

e16051 Background: Recent data have shown that cardiotoxicity represents a potentially important side-effect in patients treated with sunitinib. We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent. Methods: The medical records of 175 patients with metastatic RCC treated with sunitinib at eight Italian Institutions were retrospectively reviewed. Alterations in left ventricular ejection fraction (LVEF) and blood pressure were evaluated. Patients with pre-existing cardiac risk factors were specifically scrutinized for increased expression of cardiac changes. Results: Grade 3 hypertension was seen in 17 patients (9.7%); in twelve of these 17, hypertension developed after receiving the third sunitinib cycle. Among these 17 patients, 12 (70.6%) also experienced left-ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were of classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%). A significant univariate association for predictors of CHF were history of hypertension (p=0.008), history of coronary heart disease (p=0.0005) and prior treatment with an angiotensin converting enzyme inhibitor (ACE) (p= 0.04). Multivariate analysis suggested that a history of coronary artery disease (OR 18, 95% CI, 4–160 p 0.005) and hypertension (OR 3, 95% CI, 1.5–80 p 0.04) were the only significant independent predictors of CHF. Conclusions: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment. [Table: see text]
Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)
Authors: Michael Fridrik, Andreas L Petzer, Felix Keil, Wolfgang Willenbacher, Ulrich Jäger, Alois Lang, Johannes Andel, Otto Krieger, Wilhelm Oberaigner, Richard Greil
Journal: Blood (2010)
WALNUT-ENRICHED DIET REDUCES LIPIDS IN HEALTHY CAUCASIAN SUBJECTS, INDEPENDENT OF RECOMMENDED MACRONUTRIENT REPLACEMENT
Authors: Charlotte Bamberger, Andreas Rossmeier, Katharina Lechner, Liya Wu, Elisa Waldmann, Renee G. Stark, Julia Altenhofer, Kerstin Henze, Klaus Parhofer
Journal: Journal of the American College of Cardiology (2017)
A comparison of postoperative quality of life after open and laparoscopic gastrectomy for early gastric cancer: A multicenter, nonrandomized, controlled study (CCOG 0802).
Authors: Chie Tanaka, Kazunari Misawa, Michitaka Fujiwara, Seiji Ito, Yoshinari Mochizuki, Daisuke Kobayashi, Yoshitaka Yamamura, Masahiko Ando, Satoshi Morita, Yasuhiro Kodera
Journal: Journal of Clinical Oncology (2013)

4088 Background: The aim of this study was to compare the postoperative health-related quality of life (HRQoL) between open and laparoscopic distal gastrectomy. Methods: A multi-institutional non-randomized study was conducted, and early gastric cancer patients were prospectively enrolled and underwent distal gastrectomy either by the open or laparoscopic approach. HRQoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cancer (QLQ-C30) and the site-specific module for gastric cancer (QLQ-STO22). Questionnaires were completed at baseline and at 1, 3, 6 and 12 months postoperatively. Clinicopathological characteristics and short term outcome including postoperative morbidity and HRQoL were compared between the approaches. Results: A total of 159 patients with clinical T1 tumors were enrolled between September 2008 and January 2011. Those who were found upon pathologic examination to have ≥aStage II disease (n=14) were excluded, and the remaining 145 patients (open: n=72, laparoscopic: n=73) were analyzed. There were no significant differences between the two groups regarding age, gender, macroscopic type, depth of invasion, lymph node metastasis, and pathologic type. Laparoscopic approach was associated with longer operating time, smaller blood loss, and similar incidence of postoperative complications. At each time point, the questionnaires were sent to the data center from &gt;90% of the patients. The worst scores for most of the items were observed at 1 month postoperatively and improved thereafter. The role, emotional, cognitive, and social functioning scores were superior in the laparoscopic group at 6 and 12 months postoperatively. Symptom scales including fatigue, pain, anxiety, eating restriction, and taste problem were better in the laparoscopic group before 6 months but not at 12 months. Conclusions: Patients treated by the laparoscopic approach benefitted from better HRQoL in terms of symptoms scores during the first 6 months, while the superiority in several functioning scores lasted for 12 months.
DECREASED HEPATIC ELASTICITY IN YOUNG ADULTS AFTER BIVENTRICULAR REPAIR OF CONGENITAL HEART DISEASE
Authors: Shaija Shelby, David Danford, Jonathan Cramer, Angela Yetman, Shane Tsai, Ling Li, Scott Fletcher, Ruben Quiros-Tejeira, Shelby Kutty
Journal: Journal of the American College of Cardiology (2017)